Many oncologists recommend medical marijuana clinically despite not feeling sufficiently knowledgeable about its utility.
Patients who use medical marijuana may be more likely to use prescription drugs for both medical and nonmedical purposes.
Implementing medical or adult-use marijuana laws may reduce the rate of opioid prescribing for Medicaid enrollees.
Since the legalization of medical marijuana, clinicians must come up with appropriate responses to requests for treatment in pediatric end-of-life settings.
Various strategies to reduce opioid overdose deaths have been implemented and it has been suggested that access to medical cannabis may lead to a reduction in opioid use for pain management.
Medical marijuana laws that include a "liberal" allowance of the drug to dispensaries may contribute to reducing opioid overdose-related deaths in Medicare Part-D and Medicaid beneficiaries.
The benefits associated with medical cannabis therapy may be overestimated due to inadequate blinding in clinical trials.
Medical marijuana laws may be connected to increased rates of illicit cannabis use and cannabis use disorder, leading some users to experience negative consequences, such as motor vehicle accidents.
Medical marijuana, as a botanical and a scheduled drug does not fit the FDA paradigm for drug approval, a major impediment to its use in research.
Cannabis use disorder is also rising faster in states with legalization laws
Pot-related poison control calls and hospital discharges spike with wider availability.
Every day the staff at Clinical Pain Advisor browses the Web for stories on chronic pain, acute pain, low back pain, diabetic neuropathy, fibromyalgia and other painful health conditions that readers might have missed the day before and lists some of their favorite articles in a daily column to provide clinicians with a resource they can check first thing in the morning.
Some parents are now demanding that politicians and state legislators legalize the use of marijuana for treating epileptic children.
For Echo, reducing the therapeutic dose is key to improving compliance and providing both patients and healthcare providers with a more cost-effective therapy.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness